Resonance Specialities Ltd
Incorporated in 1989, Resonance Specialties Ltd manufactures Pyridine, Picoline, Cynopyridine and derivatives of the same[1]
- Market Cap ₹ 178 Cr.
- Current Price ₹ 154
- High / Low ₹ 154 / 77.0
- Stock P/E 12.3
- Book Value ₹ 63.4
- Dividend Yield 0.65 %
- ROCE 20.0 %
- ROE 15.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Debtor days have improved from 83.3 to 56.2 days.
Cons
- Company has a low return on equity of 10.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38 | 39 | 34 | 36 | 41 | 56 | 70 | 76 | 58 | 55 | 78 | 90 | 102 | |
| 37 | 36 | 32 | 35 | 37 | 48 | 56 | 59 | 51 | 50 | 67 | 76 | 83 | |
| Operating Profit | 1 | 3 | 2 | 1 | 5 | 8 | 14 | 17 | 7 | 5 | 11 | 14 | 19 |
| OPM % | 3.3% | 8% | 6% | 1.8% | 12% | 14% | 20% | 22% | 12% | 9% | 14% | 16% | 19% |
| 2 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 2 | 2 | |
| Interest | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 |
| Profit before tax | 1 | 2 | 1 | 0 | 5 | 7 | 15 | 16 | 7 | 4 | 9 | 14 | 19 |
| Tax % | 7% | 28% | 26% | 2,700% | 33% | 20% | 28% | 24% | 27% | 25% | 26% | 26% | |
| 1 | 1 | 1 | -1 | 3 | 6 | 11 | 12 | 5 | 3 | 7 | 10 | 15 | |
| EPS in Rs | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 5.69 | 9.01 | 12.56 |
| Dividend Payout % | 45% | 0% | 0% | 0% | 0% | 21% | 11% | 9% | 23% | 0% | 18% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | 16% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 0% |
| 3 Years: | 27% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | -2% |
| 3 Years: | 17% |
| 1 Year: | 38% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 10 | 11 | 12 | 12 | 15 | 19 | 29 | 40 | 44 | 46 | 52 | 62 |
| 3 | 2 | 4 | 3 | 0 | 0 | 1 | 0 | 2 | 4 | 3 | 2 | |
| 10 | 8 | 12 | 10 | 12 | 11 | 13 | 5 | 8 | 12 | 8 | 17 | |
| Total Liabilities | 35 | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
| 14 | 14 | 15 | 15 | 14 | 14 | 16 | 14 | 20 | 23 | 21 | 21 | |
| CWIP | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 12 |
| 20 | 18 | 25 | 22 | 23 | 25 | 38 | 42 | 45 | 48 | 54 | 57 | |
| Total Assets | 35 | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 1 | 2 | 5 | 1 | 4 | 13 | -8 | 4 | -3 | 17 | |
| -0 | -1 | -3 | -1 | -0 | -2 | -1 | -9 | 3 | -7 | 4 | -15 | |
| -2 | -2 | 2 | -1 | -4 | 1 | 0 | -2 | 1 | 0 | -1 | -2 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | 1 | 1 | 3 | 3 | -4 | -2 | -0 | -0 |
| Free Cash Flow | 1 | 2 | -2 | 1 | 5 | -1 | 3 | 13 | -16 | -0 | -4 | 14 |
| CFO/OP | 103% | 122% | 28% | 362% | 107% | 47% | 61% | 110% | -93% | 117% | -5% | 141% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 66 | 80 | 68 | 67 | 40 | 49 | 40 | 78 | 89 | 105 | 56 |
| Inventory Days | 134 | 159 | 397 | 212 | 180 | 232 | 236 | 176 | 646 | 341 | 316 | 319 |
| Days Payable | 116 | 108 | 262 | 127 | 139 | 114 | 121 | 17 | 138 | 134 | 65 | 113 |
| Cash Conversion Cycle | 117 | 117 | 215 | 152 | 108 | 158 | 164 | 198 | 587 | 295 | 356 | 263 |
| Working Capital Days | 71 | 74 | 85 | 80 | 93 | 82 | 99 | 143 | 212 | 221 | 206 | 156 |
| ROCE % | 4% | 9% | 7% | 2% | 20% | 31% | 41% | 35% | 13% | 7% | 15% | 20% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity consumption per MT of production Units/MT |
|
||||||||||
| Export revenue as % of total revenue from operations % |
|||||||||||
| HSD (diesel) consumption per MT of production Liters/MT |
|||||||||||
| R&D expenditure as % of turnover % |
|||||||||||
| Number of permanent employees count |
|||||||||||
| Coal consumption per MT of production MT/MT |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
32m - Resonance Specialties held its 37th AGM on August 4, 2026, covering FY26 adoption, dividend and related party approvals.
-
PURCHASE OF MANUFACTURING UNIT FROM KAYGEE LABORATORIES PVT LTD
2h - Board approved Q1 FY27 results and acquisition of Mandideep manufacturing facility from Kaygee Laboratories for Rs. 29.98 crore.
-
UNAUDITED FINANCIAL RESULTS FOR Q1 FY27
2h - Board approved Q1 FY27 results and purchase of Mandideep manufacturing facility for Rs 29.98 crore.
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING 04.08.2026
2h - Board approved Q1 FY26 results and ₹29.98 crore purchase of Mandideep manufacturing unit from Kaygee Laboratories.
-
Board Meeting Intimation for The Meeting Of The Board Of The Company Will Be Held On Tuesday, August 4, 2026, Inter-Alia, To Consider And Approve
23 Jul - Board to meet on August 4, 2026 to approve Q1 FY2026-27 unaudited financial results.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
The Company manufactures and markets pyridine, pyridine derivatives, picolines, and bulk drugs, with pyridine and its derivatives constituting its primary source of revenue.